Federal MOTAA 2.0: SAMHSA Funding
Official title3 Takeaways from SAMHSA’s Annual Report for SUD Treatment Pros
Federal · Relevance score 65 of 100 (related policy). medium impact.
This summary is informational and is not legal advice. Read the source text before acting on it.
What this policy change does.
- Jurisdiction
- Federal
- Bill
- MOTAA 2.0
- Published
- July 27, 2026
- Impact score
- 65 of 100, from analysis of the full text: related policy
- Primary source
- Behavioral Health Business
Impact on your practice
SAMHSA data underscores persistent treatment access crises despite epidemiological improvements, creating opportunities for therapists who specialize in SUD/co-occurring disorders. The reintroduction of MOTAA 2.0 signals legislative intent to expand MAT access, which could increase referrals and partnerships.
Key facts
- SAMHSA's 2025 National Survey shows overdose deaths declining and SUD prevalence down 3.8M, but treatment access gaps remain severe
- Only 5.5% of adults with SUD received treatment in 2025; youth access actually declined, with only 9.6% of 18-25-year-olds accessing care
- Medication-assisted treatment utilization remains extremely low: only 2.6% of alcohol use disorder cases and 15.7% of opioid use disorder cases receive MOUD
- Bipartisan MOTAA 2.0 reintroduced to address MAT access barriers and prescribing barriers
What it would mean for a practice.
The treatment access gap in substance use disorder care presents a significant revenue and referral opportunity for your practice, but only if you're positioned to capture it. While overdose deaths have declined and overall SUD prevalence dropped by 3.8 million nationally, treatment engagement remains abysmally low: only 5.5% of adults with SUD received any treatment in 2025, and just 9.6% of young adults aged 18-25 accessed care. This disparity means enormous patient populations are unidentified and untreated—potential referral sources if you develop screening protocols and partnerships with primary care, emergency departments, and community health centers. The medication-assisted treatment landscape shows particular vulnerability: only 2.6% of alcohol use disorder cases and 15.7% of opioid use disorder cases receive medication-based treatment, despite clinical evidence supporting these approaches. If MOTAA 2.0 passes, prescribing barriers for MAT will loosen, likely increasing your referral volume from physicians and psychiatric nurse practitioners who gain prescribing authority. However, this expansion could also increase insurance authorization denials and payer pushback on duration-of-treatment limits, so you'll need to document medical necessity aggressively. Co-occurring disorder treatment represents your highest-margin opportunity: 18.5 million adults have concurrent SUD and mental health conditions, yet only 12.7% receive integrated care for both. Your ability to bill collaborative care management (CoCM) codes (99492-99494) alongside individual therapy creates substantial revenue per patient, but adoption remains low due to documentation and workflow complexity. If you're not currently using CoCM billing, you're leaving thousands of dollars on the table annually per patient with concurrent diagnoses.
Background
SAMHSA's 2025 National Survey data exposes a critical paradox in substance use treatment: epidemiological conditions are improving (overdose deaths down, prevalence declining) yet treatment access and medication utilization remain stuck at crisis levels. This gap exists because the policy and reimbursement infrastructure hasn't caught up with clinical need. The reintroduction of MOTAA 2.0—bipartisan legislation aimed at reducing prescribing barriers for medication-assisted treatment—signals Congressional recognition that regulatory constraints, not clinical effectiveness, are the bottleneck. The legislation has generated controversy among major treatment organizations (AOAT, AATOD, NABH opposed it), indicating ongoing industry tension around treatment philosophy and funding models. For therapists, this moment matters because it precedes likely regulatory changes: if MOTAA 2.0 passes, more physicians will prescribe opioid medications (buprenorphine, methadone) in office-based settings, increasing your referral volume but also your documentation burden for co-occurring disorder cases. Additionally, the persistent underutilization of collaborative care management codes—designed specifically for integrated SUD/mental health treatment—reflects a reimbursement code availability problem that hasn't translated into widespread adoption, suggesting opportunity gaps exist in your billing and clinical workflow.
What you should do
- Audit your current patient panel for untreated or undertreated SUD: Calculate what percentage of your active clients with anxiety, depression, or trauma history have documented substance use screening. If screening is inconsistent, implement a universal SUD screening protocol using NIDA Quick Screen or similar validated tool at intake and annually; this surfaces hidden SUD cases and creates referral pathways.
- If you have clients with both SUD and mental health diagnoses, immediately evaluate your eligibility to bill collaborative care management (CoCM) codes 99492-99494. These codes require care coordination, behavioral health integration, and are separately billable alongside individual therapy. If you're not using them, request CPT training and implement documentation workflows to claim them; this can add $120-180 per patient per month in additional revenue.
- Monitor MOTAA 2.0 legislative status (track Congress.gov and your state psychiatric association updates). If passed, expect increased psychiatric NP and physician prescribing of buprenorphine in office-based settings. Develop a warm handoff protocol with local prescribers now so you're the default therapy referral for their newly treated patients, creating a predictable referral pipeline.
- Review your insurance authorizations for past 12 months and identify trends in denial rates, session limits, or medical necessity challenges for SUD treatment. Document which payers are most restrictive and which clinical presentation criteria they require. Use this data to strengthen your clinical notes with explicit connections to DSM-5-TR criteria, functional impairment, and treatment rationale.
- If youth are underrepresented in your SUD practice (18-25 year-olds), develop an outreach strategy targeting college health centers, community mental health clinics, and harm reduction organizations. Young adults have the lowest treatment access rate (9.6%); positioning yourself as a preferred provider in these networks could establish a sustainable referral stream.
Notable excerpts
"Among the 47.2 million individuals who are at least age 12 or older and needed SUD treatment in 2025, 84% did not receive treatment." — SAMHSA 2025 National Survey on Drug Use and Health, cited in article
"Only 5.5% of adults with SUD received treatment in 2025" and youth access rates have declined, with only 9.6% of 18-25-year-olds accessing care — SAMHSA data summary
"The recent reintroduction of the bipartisan Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0), aims to reduce barriers to access and revise prescribing strategies to improve utilization of medications for opioid use disorder." — Article reporting on legislative effort
Read the original policy source.
Primary source text, linked directly.
https://bhbusiness.com/2026/07/27/3-takeaways-from-samhsas-annual-report-for-sud-treatment-pros/
- Analysis by
- Therapy Companion policy engine
- Confidence
- high
- Analyzed
- July 28, 2026
Related policy changes.
- Relevance score65 / 100
STAT+: Trump administration quietly picks Timothy Westlake to lead mental health agency
SAMHSA leadership shapes federal funding streams, regulatory guidance, and policy direction for mental health services nationwide. A new permanent head could signal shifts in funding priorities, deprescribing initiatives, or telehealth policy that directly affect therapist reimbursement and practice requirements.medium impact - Relevance score58 / 100
RFK Jr. presents $700 million in mental health funding, but experts say grants aren’t new
While $700 million in grants being released could fund community MH programs and potentially increase therapy referrals, the lack of genuinely new funding and the focus on homelessness/severe illness means limited direct impact on most therapy practices. This is more significant for nonprofits and community mental health centers than private practitioners.medium impact - Relevance score52 / 100
[OK] HB1911: Mental health; definitions; 988 Suicide and Crisis Lifeline System; administrative structure; evaluation; workforce retention; trust fund; telecommunication fee; maximization of federal funding; effective date.
This bill directly impacts crisis system workforce stability and funding sustainability in Oklahoma. Better retention of crisis counselors and improved 988 infrastructure reduces burnout in the crisis network and improves care continuity for therapy referrals.medium impact - Relevance score45 / 100
One Student's Quick Thinking Shows Coordinated Action Through SAMHSA Program on Youth Mental Health Works
Project AWARE funding creates potential referral pipelines to therapists through schools, but the impact varies by state implementation. Therapists in states with active Project AWARE programs may see increased youth referrals and benefit from school partnerships.medium impact
Track what affects your practice.
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.